PHAT—(-25%/AH)—discloses that its NDA for vonoprazan monotherapy in erosive esophagitis is in limbo due to nitrosamine contamination: https://finance.yahoo.com/news/phathom-pharmaceuticals-provides-drug-application-210100715.html The PDUFA date had been 1/11/23.